Recent Updates
Recently added Catalysts
NKTR

Nektar Therapeutics to Webcast Presentation at the Cowen and Company 40th Annual Health Care Conference Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in ...

Key Takeaway: SAN FRANCISCO , Feb. 28, 2020 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time . The presentation will

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , Feb. 28, 2020 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR ) senior management is scheduled to present at the upcoming Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time .
The presentation will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: http://ir.nektar.com/events-and-presentations/events . This Webcast will be available for replay until April 3, 2020 .
About Nektar Nektar Therapeutics is a biopharmaceutical company with a robust, wholly-owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama and Hyderabad, India . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .
Last updated: Feb 28, 2020